Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533111 | 0.69 | — | — | |
| SCHEMBL19436193 | 0.66 | IDO1 (0.40) | ALDH1A1 | |
| SCHEMBL7004946 | 0.62 | — | — | |
| SCHEMBL7004034 | 0.62 | — | — | |
| SCHEMBL873519 | 0.62 | — | — | |
| SCHEMBL24227954 | 0.58 | APAF1 (0.33) | ALDH1A1TP53 | |
| SCHEMBL30740408 | 0.58 | TP53 (0.39) | ALDH1A1ALOX15RECQLTP53TSHR | |
| SCHEMBL10184437 | 0.57 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL31096917 | 0.56 | TP53 (0.31) | TP53 | |
| SCHEMBL31096921 | 0.56 | APAF1 (0.32) | ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120253046-A1 | PALONOSETRON METABOLITES | HELSINN HEALTHCARE S.A. (CH) | 2012-10-04 | — | — | US | disclosed |
| EP-2499137-A1 | PALONOSETRON METABOLITES | Helsinn Healthcare S.A. (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011058427-A1 | PALONOSETRON METABOLITES | HELSINN HEALTHCARE S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| EP-1240148-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | Xenova Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046157-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | XENOVA LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| US-5492914-A | ADMINISTERING TO TREAT A CONDITION CHOSEN FROM EMESIS, PSYCHOSIS, ANXIETY/DEPRESSIVE STATE, HYPERTENSION, ARRHYTHMIA AND PAIN | SYNTEX (U.S.A.) INC. (US) | 1996-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253046-A1 | PALONOSETRON METABOLITES | CYP3A5, MC2R, CYP21A2 | ALDH1A1 1453/4885ALOX15 805/4885RECQL 1549/4885 |
| US-20050143383-A1 | Pharmaceutical compounds | CHRNA10, OPRM1, SCN10A | ALDH1A1 3766/4885ALOX15 1251/4885RECQL 1715/4885 |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | ALDH1A1 2334/4885ALOX15 2895/4885RECQL 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.